

To: [5.1.2e] [5.1.2e] [5.1.2e]@rivm.nl]  
From: IMPRINT Network  
Sent: Thur 3/4/2021 8:20:20 AM  
Subject: IMPRINT Webinar on Neonates and COVID-19 & COVID-19 Vaccines | 11 March 15:00 GMT  
Received: Thur 3/4/2021 8:20:27 AM

Dear IMPRINT members,

Next week we will have the second session of our IMPRINT webinar series on topical questions relating to maternal/infant immunisation in times of COVID-19.

We have invited [5.1.2e] at St George's, University of London, and [5.1.2e] Reader in Neonatal Medicine at Imperial College London. Prof. Heath will present the **current status of COVID-19 vaccines**, [5.1.2e] will discuss the **impact of COVID-19 on the health of newborns**. Please find more details on the presentations below.

The webinar will take place on **11 March at 15:00-16:30 GMT**. The 20-minute presentations will each be followed by a Q&A session with speakers and audience that are moderated by our Network [5.1.2e] from the London School of Hygiene & Tropical Medicine and [5.1.2e] from the University of Southampton.

For **registration**, please follow this link:

[https://shtm.zoom.us/webinar/register/WN\\_K7z7D9oSQZSST1CA-QNtTg](https://shtm.zoom.us/webinar/register/WN_K7z7D9oSQZSST1CA-QNtTg)

### Presentations

#### **COVID-19: Impact on the health of newborns**

[5.1.2e], Imperial College London

Babies differ from older children with regard to their exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). I will describe the incidence, characteristics, transmission, and outcomes of SARS-CoV-2 infection in neonates who received inpatient hospital care in the UK from a prospective population-based cohort study. Neonatal SARS-CoV-2 infection is uncommon in babies admitted to hospital. Infection with neonatal admission following birth to a mother with perinatal SARS-CoV-2 infection was unlikely, and possible vertical transmission rare, supporting international guidance to avoid separation of mother and baby.

#### **COVID-19 vaccines: Current status**

[5.1.2e] St George's, University of London

It was clear at an early stage that the rapid development, distribution and administration of a vaccine to the global population would be the most effective approach to suppress the SARS-CoV-2 pandemic. The first vaccine to be given to humans was the Moderna RNA vaccine which entered its Phase I trial

an astonishing 63 days after sequence selection. This candidate represents a new vaccine platform technology and, although more traditional platforms are being employed, the use of new technologies, for which there are no previously licensed examples, is a particular feature of the COVID-19 vaccine field. A number of trials have recently reported efficacy data.

Best wishes,

5.1.2e

On behalf of the IMPRINT Management Board

5.1.2e

IMPRINT network



LINQ management GmbH, Friedbergstr. 35, 14057 Berlin, Germany

Phone: 5.1.2e

<http://www.linq-management.com/>

<http://www.imprint-network.co.uk/>

Twitter: @IMPRINT\_network

This email was sent to 5.1.2e @rivm.nl

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

LINQ management GmbH · Friedbergstr. 35 · Berlin 14057 · Germany

